Combined PI3K/Akt and Hsp90 targeting synergistically suppresses essential functions of alloreactive T cells and increases Tregs

Journal of Leukocyte Biology

Volumn 98, Issue 6, 2015, Pages 1091-1105

  Berges, Carsten ^a   Bedke, Tanja ^a   Stuehler, Claudia ^b   Khanna, Nina ^b   Zehnter, Sarah ^a   Kruhm, Michaela ^a   Winter, Nadine ^a   Bargou, Ralf C ^c   Topp, Max S ^a   Einsele, Hermann ^a   Chatterjee, Manik ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b UNIVERSITY HOSPITAL BASEL   (Switzerland)

^c UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AKT1 PROTEIN; CYCLIN DEPENDENT KINASE INHIBITOR 1; CYCLIN DEPENDENT KINASE INHIBITOR 1B; HEAT SHOCK PROTEIN 90; ISOENZYME; P110DELTA PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN KINASE B BETA; PROTEIN P53; RETINOBLASTOMA PROTEIN; UNCLASSIFIED DRUG; AKT1 PROTEIN, HUMAN; AKT2 PROTEIN, HUMAN; PHOSPHATIDYLINOSITOL 4,5 BISPHOSPHATE 3 KINASE; PIK3CD PROTEIN, HUMAN;

ACUTE GRAFT VERSUS HOST DISEASE; ALLOGENEIC STEM CELL TRANSPLANTATION; ALLOIMMUNITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; ENZYME INHIBITION; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; MORTALITY; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR GROWTH; UPREGULATION; VIRUS IMMUNITY; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CELLULAR IMMUNITY; FEMALE; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; MALE; PATHOLOGY; TRANSPLANTATION TOLERANCE;

CELL CYCLE CHECKPOINTS; CLASS I PHOSPHATIDYLINOSITOL 3-KINASES; FEMALE; GRAFT VS HOST DISEASE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNITY, CELLULAR; MALE; PROTO-ONCOGENE PROTEINS C-AKT; T-LYMPHOCYTES, REGULATORY; TRANSPLANTATION TOLERANCE;

EID: 84948984389     PISSN: 07415400     EISSN: 19383673     Source Type: Journal    
DOI: 10.1189/jlb.5A0814-413R     Document Type: Article

References (80)

1. Bishop, M. R., Alyea E. P III., Cairo, M. S., Falkenburg, J. H., June, C. H., Kröger, N., Little, R. F., Miller, J. S., Pavletic, S. Z., Porter, D. L., Riddell, S. R., van Besien, K., Wayne, A. S., Weisdorf, D. J., Wu, R. S., Giralt, S. (2011) National Cancer Institute’s First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: summary and recommendations from the organizing committee. Biol. Blood Marrow Transplant. 17, 443-454.
2. Seggewiss, R., Einsele, H. (2010) Immune reconstitution after allogeneic transplantation and expanding options for immunomodulation: an update. Blood 115, 3861-3868.
3. Ho, V. T., Soiffer, R. J. (2001) The history and future of T-cell depletion as graft-versus-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation. Blood 98, 3192-3204.
4. Stuehler, C., Mielke, S., Chatterjee, M., Duell, J., Lurati, S., Rueckert, F., Einsele, H., Bargou, R. C., Topp, M. S. (2009) Selective depletion of alloreactive T cells by targeted therapy of heat shock protein 90: a novel strategy for control of graft-versus-host disease. Blood 114, 2829-2836.
5. Garcia-Carbonero, R., Carnero, A., Paz-Ares, L. (2013) Inhibition of HSP90 molecular chaperones: moving into the clinic. Lancet Oncol. 14, e358-e369.
6. Okkenhaug, K., Vanhaesebroeck, B. (2003) PI3K in lymphocyte development, differentiation and activation. Nat. Rev. Immunol. 3, 317-330.
7. Lapinski, P. E., King, P. D. (2012) Regulation of Ras signal transduction during T cell development and activation. Am. J. Clin. Exp. Immunol. 1, 147-153.
8. Smith-Garvin, J. E., Koretzky, G. A., Jordan, M. S. (2009) T Cell activation. Annu. Rev. Immunol. 27, 591-619.
9. Basso, A. D., Solit, D. B., Chiosis, G., Giri, B., Tsichlis, P., Rosen, N. (2002) Akt forms an intracellular complex with heat shock protein 90 (Hsp90) and Cdc37 and is destabilized by inhibitors of Hsp90 function. J. Biol. Chem. 277, 39858-39866.
10. Jabbour, E., Ottmann, O. G., Deininger, M., Hochhaus, A. (2014) Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies. Haematologica 99, 7-18.
11. Huston, A., Leleu, X., Jia, X., Moreau, A. S., Ngo, H. T., Runnels, J., Anderson, J., Alsayed, Y., Roccaro, A., Vallet, S., Hatjiharissi, E., Tai, Y. T., Sportelli, P., Munshi, N., Richardson, P., Hideshima, T., Roodman, D. G., Anderson, K. C., Ghobrial, I. M. (2008) Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment. Clin. Cancer Res. 14, 865-874.
12. Chatterjee, M., Andrulis, M., St ühmer, T., Müller, E., Hofmann, C., Steinbrunn, T., Heimberger, T., Schraud, H., Kressmann, S., Einsele, H., Bargou, R. C. (2013) The PI3K/Akt signaling pathway regulates the expression of Hsp70, which critically contributes to Hsp90-chaperone function and tumor cell survival in multiple myeloma. Haematologica 98, 1132-1141.
13. Dauer, M., Obermaier, B., Herten, J., Haerle, C., Pohl, K., Rothenfusser, S., Schnurr, M., Endres, S., Eigler, A. (2003) Mature dendritic cells derived from human monocytes within 48 hours: a novel strategy for dendritic cell differentiation from blood precursors. J. Immunol. 170, 4069-4076.
14. Berges, C., Haberstock, H., Fuchs, D., Miltz, M., Sadeghi, M., Opelz, G., Daniel, V., Naujokat, C. (2008) Proteasome inhibition suppresses essential immune functions of human CD4+ T cells. Immunology 124, 234-246.
15. Dhein, J., Walczak, H., Westendorp, M. O., Bäumler, C., Stricker, K., Frank, R., Debatin, K. M., Krammer, P. H. (1995) Molecular mechanisms of APO-1/Fas(CD95)-mediated apoptosis in tolerance and AIDS. Behring Inst. Mitt. 13-20.
16. Chou, T. C. (2006) Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol. Rev. 58, 621-681.
17. Valitutti, S., Müller, S., Salio, M., Lanzavecchia, A. (1997) Degradation of T cell receptor (TCR)-CD3-zeta complexes after antigenic stimulation. J. Exp. Med. 185, 1859-1864.
18. Barnett, S. F., Defeo-Jones, D., Fu, S., Hancock, P. J., Haskell, K. M., Jones, R. E., Kahana, J. A., Kral, A. M., Leander, K., Lee, L. L., Malinowski, J., McAvoy, E. M., Nahas, D. D., Robinson, R. G., Huber, H. E. (2005) Identification and characterization of pleckstrin-homologydomain-dependent and isoenzyme-specific Akt inhibitors. Biochem. J. 385, 399-408.
19. Okkenhaug, K., Bilancio, A., Farjot, G., Priddle, H., Sancho, S., Peskett, E., Pearce, W., Meek, S. E., Salpekar, A., Waterfield, M. D., Smith, A. J., Vanhaesebroeck, B. (2002) Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice. Science 297, 1031-1034.
20. Ikeda, H., Hideshima, T., Fulciniti, M., Perrone, G., Miura, N., Yasui, H., Okawa, Y., Kiziltepe, T., Santo, L., Vallet, S., Cristea, D., Calabrese, E., Gorgun, G., Raje, N. S., Richardson, P., Munshi, N. C., Lannutti, B. J., Puri, K. D., Giese, N. A., Anderson, K. C. (2010) PI3K/p110delta is a novel therapeutic target in multiple myeloma. Blood 116, 1460-1468.
21. Su, C. H., Lan, K. H., Li, C. P., Chao, Y., Lin, H. C., Lee, S. D., Lee, W. P. (2013) Phosphorylation accelerates geldanamycin-induced Akt degradation. Arch. Biochem. Biophys. 536, 6-11.
22. Castro, J. E., Prada, C. E., Loria, O., Kamal, A., Chen, L., Burrows, F. J., Kipps, T. J. (2005) ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 106, 2506-2512.
23. Kampa-Schittenhelm, K. M., Heinrich, M. C., Akmut, F., Rasp, K. H., Illing, B., Döhner, H., Döhner, K., Schittenhelm, M. M. (2013) Cell cycledependent activity of the novel dual PI3K-MTORC1/2 inhibitor NVPBGT226 in acute leukemia. Mol. Cancer 12, 46.
24. De Zoeten, E. F., Wang, L., Sai, H., Dillmann, W. H., Hancock, W. W. (2010) Inhibition of HDAC9 increases T regulatory cell function and prevents colitis in mice. Gastroenterology 138, 583-594.
25. Patton, D. T., Garden, O. A., Pearce, W. P., Clough, L. E., Monk, C. R., Leung, E., Rowan, W. C., Sancho, S., Walker, L. S., Vanhaesebroeck, B., Okkenhaug, K. (2006) Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells. J. Immunol. 177, 6598-6602.
26. Qiao, G., Zhao, Y., Li, Z., Tang, P. Q., Langdon, W. Y., Yang, T., Zhang, J. (2013) T cell activation threshold regulated by E3 ubiquitin ligase Cbl-b determines fate of inducible regulatory T cells. J. Immunol. 191, 632-639.
27. Tran, D. Q., Andersson, J., Wang, R., Ramsey, H., Unutmaz, D., Shevach, E. M. (2009) GARP (LRRC32) is essential for the surface expression of latent TGF-beta on platelets and activated FOXP3+ regulatory T cells. Proc. Natl. Acad. Sci. USA 106, 13445-13450.
28. Noyan, F., Lee, Y. S., Zimmermann, K., Hardtke-Wolenski, M., Taubert, R., Warnecke, G., Knoefel, A. K., Schulde, E., Olek, S., Manns, M. P., Jaeckel, E. (2014) Isolation of human antigen-specific regulatory T cells with high suppressive function. Eur. J. Immunol. 44, 2592-2602.
29. Nakamura, K., Kitani, A., Fuss, I., Pedersen, A., Harada, N., Nawata, H., Strober, W. (2004) TGF-beta 1 plays an important role in the mechanism of CD4+CD25+ regulatory T cell activity in both humans and mice. J. Immunol. 172, 834-842.
30. Ouyang, W., Beckett, O., Ma, Q., Paik, J. H., DePinho, R. A., Li, M. O. (2010) Foxo proteins cooperatively control the differentiation of Foxp3+ regulatory T cells. Nat. Immunol. 11, 618-627.
31. Van de Laar, L., van den Bosch, A., Boonstra, A., Binda, R. S., Buitenhuis, M., Janssen, H. L., Coffer, P. J., Woltman, A. M. (2012) PI3K-PKB hyperactivation augments human plasmacytoid dendritic cell development and function. Blood 120, 4982-4991.
32. Bae, J., Mitsiades, C., Tai, Y. T., Bertheau, R., Shammas, M., Batchu, R. B., Li, C., Catley, L., Prabhala, R., Anderson, K. C., Munshi, N. C. (2007) Phenotypic and functional effects of heat shock protein 90 inhibition on dendritic cell. J. Immunol. 178, 7730-7737.
33. Xiao, Z., Mescher, M. F., Jameson, S. C. (2007) Detuning CD8 T cells: down-regulation of CD8 expression, tetramer binding, and response during CTL activation. J. Exp. Med. 204, 2667-2677.
34. Guinan, E. C., Boussiotis, V. A., Neuberg, D., Brennan, L. L., Hirano, N., Nadler, L. M., Gribben, J. G. (1999) Transplantation of anergic histoincompatible bone marrow allografts. N. Engl. J. Med. 340, 1704-1714.
35. Chatterjee, M., Jain, S., St ühmer, T., Andrulis, M., Ungethüm, U., Kuban, R. J., Lorentz, H., Bommert, K., Topp, M., Krämer, D., Müller-Hermelink, H. K., Einsele, H., Greiner, A., Bargou, R. C. (2007) STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90alpha and beta in multiple myeloma cells, which critically contribute to tumor-cell survival. Blood 109, 720-728.
36. Li, M., Zhang, X., Zhou, W. J., Chen, Y. H., Liu, H., Liu, L., Yang, C. M., Qan, W. B. (2013) Hsp90 inhibitor BIIB021 enhances triptolide-induced apoptosis of human T-cell acute lymphoblastic leukemia cells in vitro mainly by disrupting p53-MDM2 balance. Acta Pharmacol. Sin. 34, 1545-1553.
37. Lancet, J. E., Gojo, I., Burton, M., Quinn, M., Tighe, S. M., Kersey, K., Zhong, Z., Albitar, M. X., Bhalla, K., Hannah, A. L., Baer, M. R. (2010) Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia. Leukemia 24, 699-705.
38. Cerchietti, L. C., Lopes, E. C., Yang, S. N., Hatzi, K., Bunting, K. L., Tsikitas, L. A., Mallik, A., Robles, A. I., Walling, J., Varticovski, L., Shaknovich, R., Bhalla, K. N., Chiosis, G., Melnick, A. (2009) A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat. Med. 15, 1369-1376.
39. Usmani, S. Z., Bona, R., Li, Z. (2009) 17 AAG for HSP90 inhibition in cancer-from bench to bedside. Curr. Mol. Med. 9, 654-664.
40. Meadows, S. A., Vega, F., Kashishian, A., Johnson, D., Diehl, V., Miller, L. L., Younes, A., Lannutti, B. J. (2012) PI3Kd inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma. Blood 119, 1897-1900.
41. Herman, S. E., Johnson, A. J. (2012) Molecular pathways: targeting phosphoinositide 3-kinase p110-delta in chronic lymphocytic leukemia. Clin. Cancer Res. 18, 4013-4018.
42. Gopal, A. K., Kahl, B. S., de Vos, S., Wagner-Johnston, N. D., Schuster, S. J., Jurczak, W. J., Flinn, I. W., Flowers, C. R., Martin, P., Viardot, A., Blum, K. A., Goy, A. H., Davies, A. J., Zinzani, P. L., Dreyling, M., Johnson, D., Miller, L. L., Holes, L., Li, D., Dansey, R. D., Godfrey, W. R., Salles, G. A. (2014) PI3Kd inhibition by idelalisib in patients with relapsed indolent lymphoma. N. Engl. J. Med. 370, 1008-1018.
43. So, L., Yea, S. S., Oak, J. S., Lu, M., Manmadhan, A., Ke, Q. H., Janes, M. R., Kessler, L. V., Kucharski, J. M., Li, L. S., Martin, M. B., Ren, P., Jessen, K. A., Liu, Y., Rommel, C., Fruman, D. A. (2013) Selective inhibition of phosphoinositide 3-kinase p110a preserves lymphocyte function. J. Biol. Chem. 288, 5718-5731.
44. Blanco, B., Herrero-Sánchez, M. C., Rodríguez-Serrano, C., Sánchez-Barba, M., Del Cañizo, M. C. (2015) Profound blockade of T cell activation requires concomitant inhibition of different class I PI3K isoforms. Immunol. Res. 62, 175-188.
45. Liang, J., Slingerland, J. M. (2003) Multiple roles of the PI3K/PKB (Akt) pathway in cell cycle progression. Cell Cycle 2, 339-345.
46. Zhou, B. P., Liao, Y., Xia, W., Spohn, B., Lee, M. H., Hung, M. C. (2001) Cytoplasmic localization of p21Cip1/WAF1 by Akt-induced phosphorylation in HER-2/neu-overexpressing cells. Nat. Cell Biol. 3, 245-252.
47. Hedrick, S. M., Hess Michelini, R., Doedens, A. L., Goldrath, A. W., Stone, E. L. (2012) FOXO transcription factors throughout T cell biology. Nat. Rev. Immunol. 12, 649-661.
48. Müller, L., Schaupp, A., Walerych, D., Wegele, H., Buchner, J. (2004) Hsp90 regulates the activity of wild type p53 under physiological and elevated temperatures. J. Biol. Chem. 279, 48846-48854.
49. Zhu, J., Yamane, H., Paul, W. E. (2010) Differentiation of effector CD4 T cell populations (*). Annu. Rev. Immunol. 28, 445-489.
50. D’Souza, W. N., Chang, C. F., Fischer, A. M., Li, M., Hedrick, S. M. (2008) The Erk2 MAPK regulates CD8 T cell proliferation and survival. J. Immunol. 181, 7617-7629.
51. Blazar, B. R., Murphy, W. J., Abedi, M. (2012) Advances in graft-versushost disease biology and therapy. Nat. Rev. Immunol. 12, 443-458.
52. Maldonado, R. A., von Andrian, U. H. (2010) How tolerogenic dendritic cells induce regulatory T cells. Adv. Immunol. 108, 111-165.
53. Stenger, E. O., Turnquist, H. R., Mapara, M. Y., Thomson, A. W. (2012) Dendritic cells and regulation of graft-versus-host disease and graftversus-leukemia activity. Blood 119, 5088-5103.
54. Zöllinger, A., St ühmer, T., Chatterjee, M., Gattenlöhner, S., Haralambieva, E., Müller-Hermelink, H. K., Andrulis, M., Greiner, A., Wesemeier, C., Rath, J. C., Einsele, H., Bargou, R. C. (2008) Combined functional and molecular analysis of tumor cell signaling defines 2 distinct myeloma subgroups: Akt-dependent and Akt-independent multiple myeloma. Blood 112, 3403-3411.
55. Pal, I., Mandal, M. (2012) PI3K and Akt as molecular targets for cancer therapy: current clinical outcomes. Acta Pharmacol. Sin. 33, 1441-1458.
56. Steinbrunn, T., St ühmer, T., Sayehli, C., Chatterjee, M., Einsele, H., Bargou, R. C. (2012) Combined targeting of MEK/MAPK and PI3K/Akt signalling in multiple myeloma. Br. J. Haematol. 159, 430-440.
57. Westin, J. R. (2014) Status of PI3K/Akt/mTOR pathway inhibitors in lymphoma. Clin. Lymphoma Myeloma Leuk. 14, 335-342.
58. Furman, R. R., Sharman, J. P., Coutre, S. E., Cheson, B. D., Pagel, J. M., Hillmen, P., Barrientos, J. C., Zelenetz, A. D., Kipps, T. J., Flinn, I., Ghia, P., Eradat, H., Ervin, T., Lamanna, N., Coiffier, B., Pettitt, A. R., Ma, S., Stilgenbauer, S., Cramer, P., Aiello, M., Johnson, D. M., Miller, L. L., Li, D., Jahn, T. M., Dansey, R. D., Hallek, M., O’Brien, S. M. (2014) Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N. Engl. J. Med. 370, 997-1007.
59. Miura, Y., Thoburn, C. J., Bright, E. C., Phelps, M. L., Shin, T., Matsui, E. C., Matsui, W. H., Arai, S., Fuchs, E. J., Vogelsang, G. B., Jones, R. J., Hess, A. D. (2004) Association of Foxp3 regulatory gene expression with graft-versus-host disease. Blood 104, 2187-2193.
60. Rezvani, K., Mielke, S., Ahmadzadeh, M., Kilical, Y., Savani, B. N., Zeilah, J., Keyvanfar, K., Montero, A., Hensel, N., Kurlander, R., Barrett, A. J. (2006) High donor FOXP3-positive regulatory T-cell (Treg) content is associated with a low risk of GVHD following HLA-matched allogeneic SCT. Blood 108, 1291-1297.
61. Mavroudis, D. A., Jiang, Y. Z., Hensel, N., Lewalle, P., Couriel, D., Kreitman, R. J., Pastan, I., Barrett, A. J. (1996) Specific depletion of alloreactivity against haplotype mismatched related individuals by a recombinant immunotoxin: a new approach to graft-versus-host disease prophylaxis in haploidentical bone marrow transplantation. Bone Marrow Transplant. 17, 793-799.
62. Martin, P. J., Pei, J., Gooley, T., Anasetti, C., Appelbaum, F. R., Deeg, J., Hansen, J. A., Nash, R. A., Petersdorf, E. W., Storb, R., Ghetie, V., Schindler, J., Vitetta, E. S. (2004) Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biol. Blood Marrow Transplant. 10, 552-560.
63. Choi, J., Ritchey, J., Prior, J. L., Holt, M., Shannon, W. D., Deych, E., Piwnica-Worms, D. R., DiPersio, J. F. (2010) In vivo administration of hypomethylating agents mitigate graft-versus-host disease without sacrificing graft-versus-leukemia. Blood 116, 129-139.
64. Goodyear, O. C., Dennis, M., Jilani, N. Y., Loke, J., Siddique, S., Ryan, G., Nunnick, J., Khanum, R., Raghavan, M., Cook, M., Snowden, J. A., Griffiths, M., Russell, N., Yin, J., Crawley, C., Cook, G., Vyas, P., Moss, P., Malladi, R., Craddock, C. F. (2012) Azacitidine augments expansion of regulatory T cells after allogeneic stem cell transplantation in patients with acute myeloid leukemia (AML). Blood 119, 3361-3369.
65. Haxhinasto, S., Mathis, D., Benoist, C. (2008) The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J. Exp. Med. 205, 565-574.
66. Sauer, S., Bruno, L., Hertweck, A., Finlay, D., Leleu, M., Spivakov, M., Knight, Z. A., Cobb, B. S., Cantrell, D., O’Connor, E., Shokat, K. M., Fisher, A. G., Merkenschlager, M. (2008) T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc. Natl. Acad. Sci. USA 105, 7797-7802.
67. Mahalingam, J., Lin, C. Y., Chiang, J. M., Su, P. J., Chu, Y. Y., Lai, H. Y., Fang, J. H., Huang, C. T., Lin, Y. C. (2014) CD4⁺ T cells expressing latency-associated peptide and Foxp3 are an activated subgroup of regulatory T cells enriched in patients with colorectal cancer. PLoS One 9, e108554.
68. Rezende, R. M., Oliveira, R. P., Medeiros, S. R., Gomes-Santos, A. C., Alves, A. C., Loli, F. G., Guimarães, M. A., Amaral, S. S., da Cunha, A. P., Weiner, H. L., Azevedo, V., Miyoshi, A., Faria, A. M. (2013) Hsp65-producing Lactococcus lactis prevents experimental autoimmune encephalomyelitis in mice by inducing CD4+LAP+ regulatory T cells. J. Autoimmun. 40, 45-57.
69. Duan, W., So, T., Mehta, A. K., Choi, H., Croft, M. (2011) Inducible CD4+LAP+Foxp32 regulatory T cells suppress allergic inflammation. J. Immunol. 187, 6499-6507.
70. Ochi, H., Abraham, M., Ishikawa, H., Frenkel, D., Yang, K., Basso, A. S., Wu, H., Chen, M. L., Gandhi, R., Miller, A., Maron, R., Weiner, H. L.(2006) Oral CD3-specific antibody suppresses autoimmune encephalomyelitis by inducing CD4+ CD25-LAP+ T cells. Nat. Med. 12, 627-635.
71. Wu, H. Y., Maron, R., Tukpah, A. M., Weiner, H. L. (2010) Mucosal anti-CD3 monoclonal antibody attenuates collagen-induced arthritis that is associated with induction of LAP+ regulatory T cells and is enhanced by administration of an emulsome-based Th2-skewing adjuvant. J. Immunol. 185, 3401-3407.
72. Clarke, P. A., Hostein, I., Banerji, U., Stefano, F. D., Maloney, A., Walton, M., Judson, I., Workman, P. (2000) Gene expression profiling of human colon cancer cells following inhibition of signal transduction by 17-allylamino-17-demethoxygeldanamycin, an inhibitor of the hsp90 molecular chaperone. Oncogene 19, 4125-4133.
73. Gratwohl, A., Brand, R., Frassoni, F., Rocha, V., Niederwieser, D., Reusser, P., Einsele, H., Cordonnier, C.; Acute and Chronic Leukemia Working Parties; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. (2005) Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant. 36, 757-769.
74. Kontoyiannis, D. P., Marr, K. A., Park, B. J., Alexander, B. D., Anaissie, E. J., Walsh, T. J., Ito, J., Andes, D. R., Baddley, J. W., Brown, J. M., Brumble, L. M., Freifeld, A. G., Hadley, S., Herwaldt, L. A., Kauffman, C. A., Knapp, K., Lyon, G. M., Morrison, V. A., Papanicolaou, G., Patterson, T. F., Perl, T. M., Schuster, M. G., Walker, R., Wannemuehler, K. A., Wingard, J. R., Chiller, T. M., Pappas, P. G. (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001-2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin. Infect. Dis. 50, 1091-1100.
75. Ljungman, P. (1998) Immune reconstitution and viral infections after stem cell transplantation. Bone Marrow Transplant. 21 (Suppl 2), S72-S74.
76. Bae, J., Munshi, A., Li, C., Samur, M., Prabhala, R., Mitsiades, C., Anderson, K. C., Munshi, N. C. (2013) Heat shock protein 90 is critical for regulation of phenotype and functional activity of human T lymphocytes and NK cells. J. Immunol. 190, 1360-1371.
77. Cowen, L. E., Lindquist, S. (2005) Hsp90 potentiates the rapid evolution of new traits: drug resistance in diverse fungi. Science 309, 2185-2189.
78. Cowen, L. E., Singh, S. D., Köhler, J. R., Collins, C., Zaas, A. K., Schell, W. A., Aziz, H., Mylonakis, E., Perfect, J. R., Whitesell, L., Lindquist, S. (2009) Harnessing Hsp90 function as a powerful, broadly effective therapeutic strategy for fungal infectious disease. Proc. Natl. Acad. Sci. USA 106, 2818-2823.
79. Sun, X., Bristol, J. A., Iwahori, S., Hagemeier, S. R., Meng, Q., Barlow, E. A., Fingeroth, J. D., Tarakanova, V. L., Kalejta, R. F., Kenney, S. C. (2013) Hsp90 inhibitor 17-DMAG decreases expression of conserved herpesvirus protein kinases and reduces virus production in Epstein-Barr virus-infected cells. J. Virol. 87, 10126-10138.
80. Johnson, R. A., Wang, X., Ma, X. L., Huong, S. M., Huang, E. S. (2001) Human cytomegalovirus up-regulates the phosphatidylinositol 3-kinase (PI3-K) pathway: inhibition of PI3-K activity inhibits viral replication and virus-induced signaling. J. Virol. 75, 6022-6032.